Reducing mortality in newly diagnosed standard-risk acute promyelocytic leukemia in elderly patients treated with arsenic trioxide requires major reduction of chemotherapy: a report by the French Belgian Swiss APL group (APL 2006 trial) - Vigipallia

0 avis

Reducing mortality in newly diagnosed standard-risk acute promyelocytic leukemia in elderly patients treated with arsenic trioxide requires major reduction of chemotherapy: a report by the French Belgian Swiss APL group (APL 2006 trial)

Archive ouverte

Rahme, Ramy | Ades, Lionel | Thomas, Xavier | Guerci-Bresler, Agnes | Pigneux, Arnaud | Vey, Norbert | Raffoux, Emmanuel | Castaigne, Sylvie | Spertini, Olivier | Wittnebel, Sebastian | Marolleau, Jean Pierre | Damaj, Gandhi | Bordessoule, Dominique | Lejeune, Julie | Chevret, Sylvie | Fenaux, Pierre

Edité par CCSD ; Ferrata Storti Foundation -

International audience. No abstract available

Langue: en

Consulter en ligne

Consulter le document

Suggestions

Du même auteur

Is Arsenic Trioxide (ATO) Required in the Treatment of Standard Risk Newly Diagnosed APL? Analysis of a Randomized Trial (APL 2006) By the French Belgian Swiss APL Group

Archive ouverte | Adès, Lionel | CCSD

International audience. 57th Annual Meeting of the American-Society-of-Hematology Location: Orlando, FL Date: DEC 05-08, 2015

Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group

Archive ouverte | Adès, Lionel | CCSD

International audience

Very Long Term Follow up a Phase II Study of Post-Remission Subcutaneous (SC) Azacitidine (AZA) in Patients with AML Post-MDS or Higher-Risk (HR) MDS

Archive ouverte | Cherait, Amina | CCSD

International audience

Chargement des enrichissements...